Stevanato: Recovery Underway, Buy Confirmed
- Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds and Engineering division weakness. High-value products continue to support a robust profit outlook and with a positive sales guidance, we confirm our buy rating.
- 06/22/2025
|
USNA vs. STVN: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 06/18/2025
|
GRFS vs. STVN: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
- 06/02/2025
|
Stevanato Group S.p.A. (STVN) Q1 2025 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - Morgan Stanley Steven McLaurin Etoch - Stephens Inc Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Operator Good afternoon.
- 05/10/2025
|
Stevanato Group to Participate in Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentat.
- 05/09/2025
|
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.09 per share a year ago.
- 05/08/2025
|
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross.
- 05/08/2025
|
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 05/06/2025
|
Stevanato S p A : Group SpA ESG Report 2024
- Sustainability Report 2024 Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Contents Letter to Stakeholders 4 Methodological Note 5 Stevanato Group 7 • At a Glance 7 • Organizational Details 9 • Mission, Vision and Values 14 • The Company Structure and Main Corporate Functions 15 • Ethics, Integrity and Compliance 16 Sustainability 18 • Approach to Sustainability 18 • Certifications and Awards 21 • Participation in Organizations and Associations 23 Economic Value Creation 24 • Stakeholder Value Creation 24 Innovation and Product Responsibility 25 • Stevanato Group Products, Technologies and Services 25 • Biopharmaceutical and Diagnostic Solutions 26 • Engineering 28 • Research & Development and Innovation 29 • R&D for Drug Containment Solutions (DCS) 30 • R&D for Drug Delivery Systems (DDS) 31 • R&D for Engineering 33 • Analytical Services 37 • Product Quality and Responsibility 38 Human Capital 39 • Stevanato Group's Human Resources 39 • Employee Management and Development 42 • Occupational Health & Safety 45 Supply Chain and Procurement 47 • Responsible Supply Chain & Procurement 47 Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities Contents Environment 50 • Stevanato Group's Commitment to the Environment 50 • Energy Consumption and GHG Emissions 50 • Water Management 53 • Waste Management 55 Local Communities 57 • Local Communities' Engagement 57 Annex 59 GRI content index 62 Independent Audit Report 68 Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities Letter to Stakeholders For more than 75 years, Stevanato Group has delivered exceptional performance to meet market and customer needs, thanks to our unique value proposition of integrating our core competencies across our business lines. The passion and commitment of all of us led our Group to become a leading provider of mission-critical containment, delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Since our founding, the delivery of innovation has been a fundamental characteristic of our Group, and we embed science and technology in what we do every day to bring life-changing medicines to patients. Our goal is to be the global partner of choice to biopharma customers for the full spectrum of end-to-end solutions, from drug development through life-cycle management. Our commitment is to cooperate deeply with our partners all over the world, providing our extensive know-how, resources and enthusiasm to achieve the most successful results possible for our customers in everything we do. We want to create a reliable ecosystem to empower our customers and their ability to produce safe, easy-to-use and cost-effective treatments to improve patients' lives. We strive to support our stakeholders and we are committed to embedding sustainability in our strategic plan, policies and practices. We are committed to achieving a more sustainable and equitable future for our employees, our customers, and the communities that we serve. To accomplish this, we have developed a sustainability strategy structured in three pillars: Sustainable processes and products; Sustainable value chain; People and governance. The main goal is to pursue a regenerative business innovation journey while asserting our position as an interdependent and responsible member of the community in line with the United Nations' Sustainable Development Goals. In 2024, we progressed in our regenerative business innovation journey as shown in our fourth Sustainability Report on a voluntary basis. With regard to the environment, we advanced in our plan and we took action aligned with climate science and we have committed to set near-term emissions reductions in line with the Science-Based Target initiative. According to such GHG emissions reduction plan, we progressed mainly in respect to efficiency-related initiatives and sourcing of renewables-based electricity. We improved our waste management practices with an increase in the amount of waste recovered and diverted from landfills. With regard to the people and our aim to foster a diverse workplace, we improved in our gender balance program on females holding senior positions. With reference to the Governance area, we continue to strengthen and maintain our sustainable corporate model. We confirm our goal is to continue growing and supporting customers throughout our regenerative business innovation while making a positive impact everywhere we work and do business. We are working to improve processes, to innovate on technologies and eco-designed products and packaging. Our team is dedicated to delivering on our promise by working collaboratively to drive improvement, acting as an example of our Values and Guiding Principles. We are pursuing this important journey with confidence and determination toward an increasingly sustainable and responsible future. Franco Stevanato, Chairman and CEO Stevanato Group S.p.A. Via Molinella 17, 35017 Piombino Dese · Padova · Italy Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities Methodological Note This Sustainability Report clearly outlines Stevanato Group's environmental, social and economic achievements in a transparent and structured manner for the 2024 financial year (January 1 - December 31) aligned with the Company's financial reporting, and shows the commitment and initiatives undertaken by the Group towards its goal of sustainable development. The annual reporting cycle provides internal and external stakeholders with a representation of Stevanato Group's business performance, results and impact in relation to the main sustainability topics in the 2024 financial year. This document represents the Sustainability Report of the companies belonging to Stevanato Group S.p.A. and its subsidiaries (hereinafter also referred to as "the Company," "Stevanato," the "Stevanato Group," or "the Group"). The list of entities included is aligned with the 2024 Annual 20-F Filing. The Sustainability Report includes data about the parent company Stevanato Group S.p.A. and its subsidiaries, which are directly or indirectly consolidated on a line- by-line basis. Note that some Group companies or sites that are not operational, have not been included in the Environmental, Health & Safety data due to the limitation of scope1. Stevanato Group reports sustainability information with reference to the Global Reporting Initiative (GRI) Standards 2021. For more details on GRI Standards, please see the "GRI Content Index" section. The contents of the Sustainability Report were selected based on the results of a materiality analysis, as published in this document and described in Chapter 2. The discussion of materiality in connection with this sustainability material assessment is not an indication that such information or topics are necessarily material under U.S. federal securities laws or rules and regulations of the U.S. Securities and Exchange Commission. Quality criteria and reporting scope information was defined following GRI principles and encompassed positive 1 Not included: Stevanato Group International a.s., Ompi of America Inc (Environmental data only), Ompi of Japan Co., Ltd., Medirio SA, Perugini S.r.l., Stevanato Group N. A. S de RL de CV, and the Cisterna site (Environmental data only). In the fourth quarter of 2024, the liquidation process of Stevanato Group N.A. S. de RL de CV was completed with the cancellation from the local business register. and negative impacts, comparability, accuracy, timeliness, clarity and verifiability. Specifically, the information included in this report was taken from both the Group's IT system and the sustainability reporting package. To properly manage the reporting process, a Sustainability Reporting Procedure was set up in 2021 and updated in 2024, in line with the GRI Standards 2021, which illustrates how to prepare the Group's Sustainability Report, including the timing, tools, roles and responsibilities of the functions and individuals. To ensure the responsiveness and proper application of the procedure, the reporting process was extensively discussed and agreed upon by the working group. The information presented in this report refers to 2024 and includes a comparison with the previous year. Any information restated from previous reporting periods is indicated appropriately, where necessary, throughout the report. The information collected and reported is based on measurable data. To provide an accurate overview of the Group's performance and help ensure data reliability, the use of estimates has been limited as much as possible. If they are provided, they have been made using the best AttachmentsOriginal documentPermalinkDisclaimer Stevanato Group S.p.A. published this content on April 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2025 at 11:01 UTC.
- 04/28/2025
|
Stevanato S p A : Holding Srl Slate of Candidate Directors
- STEVANATO HOLDING S.R.L. FTE 'ANATO GROLW S.P.A. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 4"In MOLINELLA. 1.7, 35017 PiOMBINO DESE - PADOVA ITALY Pioinbino Dese. April 24. 2021 RE: SLATE OF CANDID FTE DIRECTOR.8 FOR THE .WPOINT4IEhW OF TBE BO 4RD OF DIRECTORS OF STEP IN WTO GROL P S.PM The undersigned Sergio Stevanato. in his capacity as Chairman and lepal representative of Stevaiiato Holding S.r.l. ("Stes anoto holding"). provided that: the Ordinary J'vleeting of Shareholders of Stevanato Group S p A. (respecLvely. the "ShRI'eholdei's' Meeting" and the "Company") was convened on May 23. 2025 to resolve. inlet o/in. upon the appointment of the members of the Company's Board of Directors (the "Board of Directors"). the deteruLnation of the term of the Board of Directors. the deteiiiuriaiion of the number of members of the Boar d of Directors. and the appointment of the Chairman of the Board of Directors, by nohce published on April 11. 2021 (the "Cons eniug Notice"): pursuant to Article 16 of the Company's By-laws (the "By-lows"), the Shareholders' Meeting shall appoint the members of the Board of Directors based on slates of candidate du ectors sulmutted by shareholders holding. individually or jointly with other shareholders submitting each slate, shares carrying at least 5 per cent of the total i oting rights attached to all the shares issued by the Company, Stevanato Holding holds no. 223,293.976 Class A shares of the Company, which as of the dnte hereof represent 73.73% of the Coznpany's share capital and giant Stevanato Holding math approx. 93.10% of the total voting riphts attached to the Company's shares (takuip uito accouiit the treasury shares held by the Company). pursuant to Article 16 of the By-laws and the provisions of the ConveiLnp Nohce, on behalf of Stevanato Holding. hereby submits the followup slate of candidates for the office of director of the C'ouipany: SLATE OF CANDIDATE DIRECTORS CN2DA TES' S:TATE fSiYZN 1. FRANCO STEVANATO Eligibility and integrin requi ents set firth under Arficle 2382 of the Italian Cnut PiombTno Dese (PD) - Via Molinella n. 17 CAP 3S017 Capitale sociale sottoscritto € 100.000,00 i.v. Codice fiscale e Partita 1.U.A 05099030289 lscritta R.E.A. n. PD - 442934 - professionalism and skills required to perform the tasks entrusted to the Company's Directors. 2. SERGIO STEVANATO Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors. 3. MADHAVAN BALACHANDRAN Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company. 4. FABRIZIO BONANNI Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company. 5. WILLIAM FEDERICI Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company; accounting or related financial management expertise required under the United States regulations and the New York Stock Exchange regulations applicable to the Company. 6. KAREN FLYNN Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company. 7. SUE JEAN LIN Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company; accounting or related financial management expertise required under the United States regulations and the New York Stock Exchange regulations applicable to the Company. 8. ELISABETTA MAGISTRETTI Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company; accounting or related financial management expertise required under the United States regulations and the New York Stock Exchange regulations applicable to the Company; enrolled in the Italian Register of Legal Auditors (Registro dei revisori legali) established at the Ministry of Economy and Finance pursuant to Italian Legislative Decree no. 39/2010. 9. DONALD EUGENE MOREL JR. Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company; accounting or related financial management expertise required under the United States regulations and the New York Stock Exchange regulations applicable to the Company. 10. LUCIANO SANTEL Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors; independence requirements set forth under Article 2399 of the Italian Civil Code; independence requirements set forth under the United States law and the New York Stock Exchange regulations applicable to the Company; financial literacy requirements set forth under the Unites States regulations and the New York Stock Exchange regulations applicable to the Company; accounting or related financial management expertise required under the United States regulations and the New York Stock Exchange regulations applicable to the Company. 11. ALVISE SPINAZZI Eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code; professionalism and skills required to perform the tasks entrusted to the Company's Directors. The undersigned also submits to the Shareholders' Meeting, on behalf of Stevanato Holding, the proposals to: appoint the abovementioned candidate directors as members of the Board of Directors for the period of one financial year, i.e. for the period elapsing from the date of the Shareholders' Meeting to the date of the approval of the financial statements of the Company ending on December 31, 2025; and appoint Mr. Franco Stevanato, if elected as director of the Company, as Chairman of the Board of Directors of the Company pursuant to Article 17.3 of the By-laws. The following documents are attached hereto: a curriculum vitae of each candidate director; the statements by which each candidate director accepts his/her candidacy and certifies, under his/her own responsibility, that he/she possesses the eligibility and integrity requirements provided for in Article 15.3 of the Bylaws, and, as the case may be, the independence requirements provided for in Article 15.4 of the By-laws, as well as the independence, expertise and competence requirements provided for in Articles 23.3, 23.4 and 23.5 of the By-laws. Stevanato Holding S.r.l. Firmato digitalmente da: Stevanato Sergio Firmato il 24/04/2025 11:39 Seriale Certificato: 3636070 Valido dal 06/06/2024 al 06/06/2027 InfoCamere Qualified Electronic Signature CA (Sergio Stevanato) STATEFIENT ACCEPTANCr or «osiiNai'ioN roR THE OrFicE or DiRECTOR AND/OR MEMBER OF THE AUDrr COâlMITTEE or sTEVANATO GROtIP S.P.A. AND FULFILLMENT OF THE RELEYAh'I' REQUIREM ENTS SET FORJ'H IINDER THE A1'PL1CABLE LA t'S AND IFI'-LAWS' PROVISIONS I, the undersigned Mr./Ms./Dr. Franco Stevanaio born in Venice on 27/I 2/1973 , ID Card/Passport no. , with reference to: the General Meeting of the Shareholders of Stevanato Group S.p.A (the "Com pany") convened on May 23, 2025 (the "General Meeting") to resolve upon, Enter alia, the appointment of the members of the Board of Directors for the period ending on the date of approval of the Company's financial statements for the financial year ending on Decembu 3 , 2025, and - the slate of candidate dii-ectors to be presented by Stevbnato Holding S.r.l. to the General Meeting for the appointment of the members of the Board of Directors for said period, pursuant to Article 16 of the Company's bylaws, in my capacity aS l2omineB for the office of Director and/or member of the Audit Committee of the Company, pursuant to Article 16.3 of the Company's by-laws, hereby STATE AND CERTIFY as of the date hereof, to meet the eligibility and integrity requirements set forth under Article 2382 of the Italian Civil Code (*) and possess the professionalism and skills required to perform the tasks entrusted to the Company's Directors ('); not to have been disqualified from holding the office of company director in a Member State of the European Union other than lialy ); n to iiicet the independence requirements set forth under article 2399 of the Italian Civil Code (**) ('); n to be enrolled in the Italian Register of Legal Auditors {Regish-o dei reviso/ f legali) established at the Ministry of Economy and Finance pursuant to Italian Legislative Decree no. 39/20 10 ('); n to meet the requirements of independence set forih under the United States laws and regulations and the New York Stock Exchange regulations applicable to the Company (***) ( ); ' All nominees for the offices of Director and member of the Audit Comminee Of the Company must meet such requirements. ' All nominees for the offices of Director and member of the Audit Committee pt the Company must meet such requirement. At least one third of nominees for the offices of Director and member of the Audit Committee of the Company and ali nominces for the office ot' member of the Audit Committee of the Company musi meet such requirements. 4 At least one nominee for the office of member of the Audit Committee of the Company must meet such requirement. AH nominees fr›r the office of member of the Audit Committee of the Company must meet such requirements. AttachmentsOriginal documentPermalinkDisclaimer Stevanato Group S.p.A. published this content on April 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2025 at 11:01 UTC.
- 04/28/2025
|
Stevanato S p A : PWC Stevanato Group SpA Report on the Audit of the Consolidated Financial Statements
- Independent auditor's report in accordance with article 14 of Legislative Decree No. 39 of 27 January 2010 To the shareholders of Stevanato Group SpA aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Report on the Audit of the Consolidated Financial Statements Opinion We have audited the consolidated financial statements of Stevanato Group (the Group), which comprise the consolidated statement of financial position as of 31 December 2024, the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity, consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information. In our opinion, the consolidated financial statements give a true and fair view of the financial position of the Group as of 31 December 2024, and of the result of its operations and cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and adopted by the European Union. Basis for Opinion We conducted our audit in accordance with International Standards on Auditing (ISA Italia). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of this report. We are independent of Stevanato Group SpA pursuant to the regulations and standards on ethics and independence applicable to audits of financial statements under Italian law. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Responsibilities of the Directors and the Audit Committee for the Consolidated Financial Statements The directors are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and adopted by the European Union and, in the terms prescribed by law, for such internal control as they determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. The directors are responsible for assessing the Group's ability to continue as a going concern and, in preparing the consolidated financial statements, for the appropriate application of the going concern basis of accounting, and for disclosing matters related to going concern. In preparing the consolidated financial statements, the directors use the going concern basis of accounting unless they either intend to liquidate Stevanato Group SpA or to cease operations, or have no realistic alternative but to do so. The Audit Committee ("Comitato per il controllo sulla gestione") is responsible for overseeing, in the terms prescribed by law, the Group's financial reporting process. Auditor's Responsibilities for the Audit of the Consolidated Financial Statements Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISA Italia) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial statements. As part of our audit conducted in accordance with International Standards on Auditing (ISA Italia), we exercised our professional judgement and maintained professional scepticism throughout the audit. Furthermore: We identified and assessed the risks of material misstatement of the consolidated financial statements, whether due to fraud or error; we designed and performed audit procedures responsive to those risks; we obtained audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control; We obtained an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control; We evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors; We concluded on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern; We evaluated the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation; We obtained sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion on the consolidated financial statements. We communicated with those charged with governance, identified at an appropriate level as required by ISA Italia regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit. Report on Compliance with other Laws and Regulations Opinions and statement in accordance with article 14, paragraph 2, letters e), e-bis) and e-ter) of Legislative Decree No. 39/10 The directors of Stevanato Group SpA are responsible for preparing a report on operations of Stevanato Group as of 31 December 2024, including its consistency with the relevant financial statements and its compliance with the law. We have performed the procedures required under auditing standard (SA Italia) No. 720B in order to: express an opinion on the consistency of the report on operations with the consolidated financial statements; express an opinion on the compliance with the law of the report on operations; issue a statement on material misstatements, if any, in the report on operations. In our opinion, the report on operations is consistent with the consolidated financial statements of Stevanato Group as of 31 December 2024. Moreover, in our opinion, the report on operations is prepared in compliance with the law. With reference to the statement referred to in article 14, paragraph 2, letter e-ter), of Legislative Decree No. 39/10, issued on the basis of our knowledge and understanding of the Group and its environment obtained in the course of the audit, we have nothing to report. Treviso, 22 April 2025 PricewaterhouseCoopers SpA Signed by Scott Cunningham (Partner) This report has been translated into English from the Italian original solely for the convenience of international readers AttachmentsOriginal documentPermalinkDisclaimer Stevanato Group S.p.A. published this content on April 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2025 at 11:01 UTC.
- 04/28/2025
|
Stevanato S p A : PWC Stevanato Group SpA Report on the Audit of the Financial Statements
- Independent auditor's report in accordance with article 14 of Legislative Decree No. 39 of 27 January 2010 To the shareholders of Stevanato Group SpA aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Report on the Audit of the Financial Statements Opinion We have audited the financial statements of Stevanato Group SpA (the Company), which comprise the statement of financial position as of 31 December 2024, the income statement, statement of comprehensive income, statement of changes in equity, statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information. In our opinion, the financial statements give a true and fair view of the financial position of the Company as of 31 December 2024, and of the result of its operations and cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and adopted by the European Union. Basis for Opinion We conducted our audit in accordance with International Standards on Auditing (ISA Italia). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of this report. We are independent of the Company pursuant to the regulations and standards on ethics and independence applicable to audits of financial statements under Italian law. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Responsibilities of the Directors and the Audit Committee for the Financial Statements The directors are responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and adopted by the European Union and, in the terms prescribed by law, for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The directors are responsible for assessing the Company's ability to continue as a going concern and, in preparing the financial statements, for the appropriate application of the going concern basis of accounting, and for disclosing matters related to going concern. In preparing the financial statements, the directors use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so. The Audit Committee ("Comitato per il controllo sulla gestione") is responsible for overseeing, in the terms prescribed by law, the Company's financial reporting process. Auditor's Responsibilities for the Audit of the Financial Statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISA Italia) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements. As part of our audit conducted in accordance with International Standards on Auditing (ISA Italia), we exercised our professional judgement and maintained professional scepticism throughout the audit. Furthermore: We identified and assessed the risks of material misstatement of the financial statements, whether due to fraud or error; we designed and performed audit procedures responsive to those risks; we obtained audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control; We obtained an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control; We evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors; We concluded on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; We evaluated the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. We communicated with those charged with governance, identified at an appropriate level as required by ISA Italia, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit. Report on Compliance with other Laws and Regulations Opinions and statement in accordance with article 14, paragraph 2, letters e), e-bis) and e-ter) of Legislative Decree No. 39/10 The directors of Stevanato Group SpA are responsible for preparing a report on operations of Stevanato Group SpA as of 31 December 2024, including its consistency with the relevant financial statements and its compliance with the law. We have performed the procedures required under auditing standard (SA Italia) No. 720B in order to: express an opinion on the consistency of the report on operations with the financial statements; express an opinion on the compliance with the law of the report on operations; issue a statement on material misstatements, if any, in the report on operations. In our opinion, the report on operations is consistent with the financial statements of Stevanato Group SpA as of 31 December 2024. Moreover, in our opinion, the report on operations is prepared in compliance with the law. With reference to the statement referred to in article 14, paragraph 2, letter e-ter), of Legislative Decree No. 39/10, issued on the basis of our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have nothing to report. With reference to the statement referred to in article 14, paragraph 2, letter e), of Legislative Decree No. 39/10, issued on the basis of our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have nothing to report. Treviso, 22 April 2025 PricewaterhouseCoopers SpA Signed by Scott Cunningham (Partner) This report has been translated into English from the Italian original solely for the convenience of international readers AttachmentsOriginal documentPermalinkDisclaimer Stevanato Group S.p.A. published this content on April 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2025 at 11:01 UTC.
- 04/28/2025
|
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss fina.
- 04/24/2025
|
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company will present on Tuesday, March 18, at 3.00 p.m. (ET). A live webcast will be available on the Company.
- 03/11/2025
|
Stevanato: Ramping Syringe Demand, Buy Confirmed
- Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war.
- 03/09/2025
|
Stevanato Group S.p.A. (STVN) Q4 2024 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Operator Good afternoon.
- 03/06/2025
|
Stevanato Group (STVN) Meets Q4 Earnings Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.20 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago.
- 03/06/2025
|
Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represent.
- 03/06/2025
|
Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025,.
- 02/24/2025
|
USNA or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 02/14/2025
|
USNA vs. STVN: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
- 01/29/2025
|
UTHR vs. STVN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 01/08/2025
|
Stevanato Group to Present at Upcoming Investor Conference
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live event webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" sec.
- 01/07/2025
|
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
- Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target.
- 11/13/2024
|
Stevanato Group to Present at Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at.
- 11/11/2024
|
CPRX vs. STVN: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
- 11/06/2024
|
Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Stephens Dave Windley - Jefferies Paul Knight - KeyBanc Capital Markets Dan Leonard - UBS Curtis Moiles - BNP Paribas Exane Operator Good afternoon.
- 11/05/2024
|
Stevanato Group (STVN) Q3 Earnings Match Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago.
- 11/05/2024
|
Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discus.
- 10/22/2024
|
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
- Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/22/2024
|
CPRX or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 10/21/2024
|
CPRX or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 10/04/2024
|
Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-c.
- 10/01/2024
|
Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges. The Alliance.
- 09/26/2024
|
Stevanato Group to Present at Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the Morgan Stanley Healthcare Conference in New York on Friday, September 6, 2024 at 7:00 a.m. (ET), and at the Bank of America Global Healthcare Conference in L.
- 08/29/2024
|
SDZNY vs. STVN: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
- 08/12/2024
|
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
- Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript
- 08/10/2024
|
Stevanato Group (STVN) Q2 Earnings Match Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.15 per share a year ago.
- 08/06/2024
|
Stevanato Group Reports Financial Results for the Second Quarter of 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total reven.
- 08/06/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/26/2024
|
STVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Stevanato Group S.p.A. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/25/2024
|
Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss f.
- 07/25/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Stevanato Group S.p.A. (STVN) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/24/2024
|
Stevanato Group S.p.A. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - STVN
- NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/22/2024
|
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
- Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/19/2024
|
Levi & Korsinsky Reminds Stevanato Investors of the Ongoing Investigation into Potential Violations of Securities Laws - STVN
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/19/2024
|
STVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Stevanato Group S.p.A.
- NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/18/2024
|
Stevanato Group S.p.A. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - STVN
- NEW YORK, NY / ACCESSWIRE / July 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/17/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/16/2024
|
ATTENTION Stevanato Group S.p.A. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/15/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/12/2024
|
Levi & Korsinsky Reminds Stevanato Investors of the Ongoing Investigation into Potential Violations of Securities Laws - STVN
- NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/11/2024
|
Levi & Korsinsky Announces an Investigation on Behalf of Stevanato Group S.p.A. (STVN) Shareholders Who May Have Been Affected by Fraud
- NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/10/2024
|
STVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Stevanato Group S.p.A. investment
- NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/09/2024
|
Investors who lost money on Stevanato Group S.p.A. should contact Levi & Korsinsky about an ongoing investigation - STVN
- NEW YORK, NY / ACCESSWIRE / July 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/08/2024
|
Stevanato Group S.p.A. (STVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
- NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/05/2024
|
STVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Stevanato Group S.p.A.
- NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/03/2024
|
STVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Stevanato Group S.p.A. Investment
- NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/02/2024
|
Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.
- NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 07/01/2024
|
Levi & Korsinsky Reminds Stevanato Investors of the Ongoing Investigation into Potential Violations of Securities Laws - STVN
- NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/28/2024
|
Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.
- NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/27/2024
|
Stevanato Group S.p.A. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - STVN
- NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/25/2024
|
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Stevanato Group S.p.A. (STVN)
- NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/24/2024
|
Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.
- NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/21/2024
|
STVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Stevanato Group S.p.A. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/17/2024
|
An Investigation Has Commenced on Behalf of Stevanato Group S.p.A. Shareholders.
- NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/11/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/07/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Stevanato Group S.p.A. (STVN) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/06/2024
|
Lost Money on Stevanato Group S.p.A.(STVN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/05/2024
|
Stevanato Group S.p.A. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- STVN
- NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/04/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 06/03/2024
|
Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN
- NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 05/31/2024
|
Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant. Located just a few kilometers from the Group's first historic plant in Latina, the new site covers an area of 65,000 square meters and employs around 200 people. The facility started commercial production.
- 05/30/2024
|
Stevanato: Destock Pressures, Long-Term Upside
- Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand.
- 05/29/2024
|
Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement w.
- 05/28/2024
|
Stevanato Group Announces Results of Annual General Meeting
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report p.
- 05/24/2024
|
Stevanato Group to Present at Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4, 2024 at 4:00 p.m. (CT), and at the Jefferies Healthcare Conference in New York City on T.
- 05/23/2024
|
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 05/20/2024
|
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Stevanato Group S.p.A. (STVN)
- NEW YORK, NY / ACCESSWIRE / May 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 05/20/2024
|
Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.
- NEW YORK, NY / ACCESSWIRE / May 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
- 05/17/2024
|
Stevanato Group S.p.A. (STVN) Q1 2024 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lisa Miles – Investor Relations Franco Stevanato – Executive Chairman Marco Dal Lago – Chief Financial Officer Franco Moro – Chief Executive Officer Conference Call Participants Michael Ryskin – Bank of America Paul Knight – KeyBanc Patrick Donnelly – Citi Sam Martin – William Blair Tucker Remmers – Jefferies Curtis Moiles – BNP Paribas Exane Lisa Miles Good morning, and thanks for joining us.
- 05/11/2024
|
USNA or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
- 05/02/2024
|
Stevanato Group to Present at the Bank of America Securities Healthcare Conference
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024. The Company will present on Wednesday, May 15, 2024 at 11:20 a.m. (PT). A live webcast will be available.
- 05/01/2024
|
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss fina.
- 04/25/2024
|
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
- Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2024
|
International Companies Drive Diabesity Innovation
- International Companies Drive Diabesity Innovation
- 03/29/2024
|
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters' option to purchase 1,905,000 ad.
- 03/26/2024
|
Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share. Stevanato Group is offering 6,350,000 ordinary shares (the.
- 03/21/2024
|
Stevanato Group Announces Public Offering of Ordinary Shares
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares. Stevanato Group is offering $150,000,000 of its ordinary shares (the “Company Offering”), and Stevanato Holding S.
- 03/20/2024
|
Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March 20, 2024. The Company will present on Tuesday, March 19, 2024 at 1:30 p.m. (ET). A.
- 03/11/2024
|
TAK or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 03/11/2024
|
Stevanato Group S.p.A. (STVN) Q4 2023 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President of Investor Relations Franco Stevanato - Executive Chairman Marco Dal Lago - Chief Financial Officer Franco Moro - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citi Jacob Johnson - Stephens Matt Larew - William Blair Derik de Bruin - Bank of America Larry Solow - CJS Securities David Windley - Jefferies John Sourbeer - UBS Paul Knight - KeyBanc Lisa Miles Good morning and thank you for joining us.
- 03/07/2024
|
Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023. Fourth Quarter and FY 2023 Highlights (compared with the same period last year) Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represente.
- 03/07/2024
|
Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7, 202.
- 02/22/2024
|
Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group's new EZ-fill® Kit.
- 01/24/2024
|
Stevanato Group to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8, 2024 to January 11, 2024 in San Francisco, California. The Company will present on Wednesday, January 10th at 8:15 a.m.(PT). A live webcast will.
- 01/03/2024
|
Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, announced today that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor Business Media. The Pharma Innovation Awards represent an annual recognition of new technologies and services that aim.
- 11/16/2023
|
Stevanato Group to Present at the Jefferies London Healthcare Conference
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Jefferies London Healthcare Conference taking place from November 14, 2023 to November 16, 2023. The Company will present on Wednesday, November 15, 2023 at 10:00 a.m. GMT. A live webcast will be available on the Company.
- 11/09/2023
|
Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript
- Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript
- 10/31/2023
|
Stevanato Group (STVN) Q3 Earnings Meet Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.14 per share a year ago.
- 10/31/2023
|
TAK vs. STVN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 10/27/2023
|
Stevanato Group to Report Third Quarter 2023 Financial Results on October 31, 2023
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, October 31, 2023 to discu.
- 10/17/2023
|
USNA or STVN: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 10/11/2023
|
Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
- Stevanato Group is a global provider of drug containment with a CAPEX growth plan to support growth and reach new geographical diversification. Balance sheet flexibility thanks to margin expansions. Strong secular tailwinds in biologics support the company's economic moat. Higher guidance coupled with solid results makes Stevanato a buy.
- 09/15/2023
|
GRFS or STVN: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/14/2023
|
All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy
- Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/11/2023
|
Stevanato Group S.p.A. (STVN) Q2 2023 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q2 2023 Earnings Conference Call July 28, 2023 8:30 AM ET Company Participants Lisa Miles - Senior Vice President, Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Paul Knight - KeyBanc David Windley - Jefferies Derik de Bruin - Bank of America Drew Ranieri - Morgan Stanley Matt Larew - William Blair Operator Good afternoon.
- 07/28/2023
|
Stevanato Group to Report Second Quarter 2023 Financial Results on July 28, 2023
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Friday, July 28, 2023 to discuss fina.
- 07/14/2023
|
Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?
- Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/19/2023
|
Stevanato Group: Undeniable Quality, But Lacking Upside
- Stevenato Group is a Pharmaceutical Manufacturing leader, generating 15% net income margins annually. The company has developed a global customer base over the course of its 70-year operating history and continues to add new clients with each passing quarter. The current valuation appears to be maxed out, but potential investors should add this high-quality company to their watchlists.
- 06/14/2023
|
Stevanato Group to Present at Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. On June 6, 2023, management will present at the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois at 2:40 p.m. CT, and on June 8, 2023, management will present at the J.
- 05/24/2023
|
Stevanato Group S.p.A. (STVN) Q1 2023 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Lisa Miles - Senior Vice President, Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Lago - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Paul Knight - KeyBanc Capital Markets Tim Daley - Wells Fargo Dave Windley - Jefferies John Sourbeer - UBS Operator Good afternoon.
- 05/06/2023
|
As Covid Wanes, Maker Of Glass Vials, Other Medical Products Misses Estimates
- Growth stock Stevanato plunged after first quarter earnings as sales from Covid related services fell; maintained its full year outlook The post As Covid Wanes, Maker Of Glass Vials, Other Medical Products Misses Estimates appeared first on Investor's Business Daily.
- 05/04/2023
|
Stevanato Group (STVN) Q1 Earnings Lag Estimates
- Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.12 per share a year ago.
- 05/04/2023
|
Stevanato Group to Present at BofA Securities Healthcare Conference
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the upcoming BofA Securities Healthcare Conference at the Encore hotel in Las Vegas that will take place from May 9, 2023 to May 11, 2023. The Company will present on Tuesday, May 9, 2023 at 9:20 a.m. PT. A live audio webcas.
- 05/02/2023
|
Stevanato Group S.p.A. (STVN) Hit a 52 Week High, Can the Run Continue?
- Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 04/18/2023
|
Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m.
- 04/17/2023
|
Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?
- Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 03/30/2023
|
Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum taking place on March 21 and March 22, 2023. The Company will present on Tuesday, March 21, 2023 at 11:15 a.m. ET.
- 03/14/2023
|
Surging Earnings Estimates Signal Upside for Stevanato (STVN) Stock
- Stevanato (STVN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 03/07/2023
|
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
- Stevanato (STVN) delivered earnings and revenue surprises of 18.75% and 9.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2023
|
Stevanato Group to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 2, 2023
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m.
- 02/16/2023
|
Stevanato Group S.p.A. (STVN) Q3 2022 Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Lisa Miles - SVP Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Elizabeth Speyer - Citigroup Inc. Derik De Bruin - Bank of America Paul Knight - KeyBanc Capital Markets David Windley - Jefferies Madeline Mollman - William Blair Timothy Daley - Wells Fargo John Sourbeer - UBS Operator Good afternoon.
- 11/12/2022
|
ASRT vs. STVN: Which Stock Is the Better Value Option?
- ASRT vs. STVN: Which Stock Is the Better Value Option?
- 10/03/2022
|
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
- ASRT vs. STVN: Which Stock Is the Better Value Option?
- 09/14/2022
|
Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q2 2022 Results - Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Lisa Miles - Investor Relations Franco Stevanato - Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Justin Lin - William Blair Derik De Bruin - Bank of America Patrick Donnelly - Citi Steven Couche - Jefferies John Sourbeer - UBS Operator Good afternoon.
- 08/06/2022
|
Stevanato Group to Report Second Quarter 2022 Financial Results on August 4, 2022
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. (EST). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EST) on Thursday, August 4, 2022 to disc
- 07/22/2022
|
JAZZ vs. STVN: Which Stock Is the Better Value Option?
- JAZZ vs. STVN: Which Stock Is the Better Value Option?
- 07/21/2022
|
JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?
- JAZZ vs. STVN: Which Stock Is the Better Value Option?
- 07/05/2022
|
Stevanato Group to Present at Upcoming Investor Conferences
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. On June 7, 2022, Stevanato management will present at the 42nd Annual William Blair Growth Stock Conference in Chicago at 2:40 PM CST and on June 9, 2022, at the Jefferies Healthcare Confer
- 06/01/2022
|
Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q1 2022 Results - Earnings Call Transcript
- Stevanato Group S.p.A. (NYSE:STVN ) Q1 2022 Results Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Miles - Head of Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer and Chief Operating Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America John Kreger - William Blair Dave Windley - Jefferies Paul Knight - KeyBanc Tim Daley - Wells Fargo John Sourbeer - UBS Drew Ranieri - Morgan Stanley Lisa Miles Good morning, and thank you for joining us.
- 05/14/2022
|
Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the first quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14
- 04/27/2022
|
Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Management will present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022. A live audio webcast will be available on the Company's website at www.st
- 03/17/2022
|
Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q4 2021 Results - Earnings Call Transcript
- Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q4 2021 Results - Earnings Call Transcript
- 03/08/2022
|
Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Q4 & YE 2021 Earnings notification
- 02/18/2022
|
Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q3 2021 Results - Earnings Call Transcript
- Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)
- PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has been recognized as a winner of Pharma Manufacturing magazine's 2021 Pharma Innovation Award for its AI-ready Vision Robot Unit (VRU) - a robotic human-like inspection unit. Stevanato Group's VRU inspection system is an autonomous module capable of automatically
- 10/19/2021
|
Stevanato Group Initiates Construction on New U.S. Facility
- PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an a
- 10/04/2021
|
Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q2 2021 Results - Earnings Call Transcript
- Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q2 2021 Results - Earnings Call Transcript
- 08/19/2021
|
Stevanato Group Announces Second Quarter 2021 Financial Results
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance. Second Quarter 2021 Highlights (compared to the same period last year) and Guidance Revenue grew 26% to €204.0 million; all growth was organic Gross margins incr
- 08/19/2021
|
Stevanato Group to Report Second Quarter Financial Results on August 19
- PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021. The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on August 19, 2021. Management w
- 08/11/2021
|
Stevanato Group makes NYSE debut
- Franco Stevanato joins 'The Exchange' to speak about his company's NYSE debut today. The Stevanato Group makes glass vials and other components critical to distributing Covid-19 vaccines.
- 07/16/2021
|
7 Companies Begin Trading. Here's How They're Doing.
- The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
- 07/16/2021
|
Vaccine vial maker Stevanato raises $672 million in U.S. IPO
- Stevanato Group S.p.A., an Italian maker of glass vials for COVID-19 vaccines and other healthcare products, raised $672 million in a downsized initial public offering on Thursday.
- 07/15/2021
|
